References
- Kaplan S, Ehlken B, Hamann X. The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany. Curr Med Res Opin 2018. doi: 10.1080/03007995.2018.1499507
- Harish S, Bhuvana K, Bengalorkar GM, et al. Flupirtine: clinical pharmacology. J Anaesthesiol Clin Pharmacol 2012;28:172-7
- Yeung S, Schwake M, Pucovsky V, et al. Bimodal effects of the Kv7 channel activator retigabine on vascular K + currents [Research Support, Non-U.S. Gov't]. Br J Pharmacol 2008;155:62-72
- Anderson N, Borlak J. Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting [Case Reports Comparative Study Research Support, Non-U.S. Gov't]. PLoS One 2011;6:e25221
- European Medicines Agency. PRAC recommends restricting the use of flupirtinecontaining medicines. London, UK: European Medicines Agency; 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500144453.pdf [Last accessed October 19, 2018]
- Douros A, Bronder E, Andersohn F, et al. Flupirtine-induced liver injury—seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database [Case Reports Research Support, Non-U.S. Gov't]. Eur J Clin Pharmacol 2014;70:453-9
- European Medicines Agency. PRAC recommends that the marketing authorisation of the painkiller flupirtine be withdrawn. London, UK: European Medicines Agency; 2018. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Flupirtine-containing_medicinal_products/human_referral_prac_000069.jsp&mid=WC0b01ac05805c516f [Last accessed October 19, 2018]
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module XVI– Risk minimisation measures: selection of tools and effectiveness indicators. London, UK: European Medicines Agency; 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144010.pdf [Last accessed October 19, 2018]
- Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European Union: a review of the implementation and effectiveness of measures in the United Kingdom by one marketing authorisation holder. Pharm Med 2017;31:101-12
- European Medicines Agency. Towards optimising risk minimisation measures. Report on EMA’s workshop on risk minimisation measures. London, UK: European Medicines Agency; 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/12/WC500198810.pdf [Last accessed October 19, 2018]